EP3976629A4 - Peptides se liant au récepteur de l'hormone anti-müllérienne - Google Patents

Peptides se liant au récepteur de l'hormone anti-müllérienne Download PDF

Info

Publication number
EP3976629A4
EP3976629A4 EP20814439.4A EP20814439A EP3976629A4 EP 3976629 A4 EP3976629 A4 EP 3976629A4 EP 20814439 A EP20814439 A EP 20814439A EP 3976629 A4 EP3976629 A4 EP 3976629A4
Authority
EP
European Patent Office
Prior art keywords
receptor binding
hormone receptor
binding peptides
mullerian hormone
mullerian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20814439.4A
Other languages
German (de)
English (en)
Other versions
EP3976629A1 (fr
Inventor
Laura DETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3976629A1 publication Critical patent/EP3976629A1/fr
Publication of EP3976629A4 publication Critical patent/EP3976629A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP20814439.4A 2019-05-31 2020-05-30 Peptides se liant au récepteur de l'hormone anti-müllérienne Pending EP3976629A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855427P 2019-05-31 2019-05-31
PCT/US2020/035472 WO2020243679A1 (fr) 2019-05-31 2020-05-30 Peptides se liant au récepteur de l'hormone anti-müllérienne

Publications (2)

Publication Number Publication Date
EP3976629A1 EP3976629A1 (fr) 2022-04-06
EP3976629A4 true EP3976629A4 (fr) 2023-11-22

Family

ID=73552433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20814439.4A Pending EP3976629A4 (fr) 2019-05-31 2020-05-30 Peptides se liant au récepteur de l'hormone anti-müllérienne

Country Status (5)

Country Link
US (2) US11535676B2 (fr)
EP (1) EP3976629A4 (fr)
AU (1) AU2020282359A1 (fr)
CA (1) CA3139956A1 (fr)
WO (1) WO2020243679A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112908475A (zh) * 2021-04-22 2021-06-04 北京大学第三医院（北京大学第三临床医学院） 用于评估受试者卵巢储备功能的系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166712A1 (fr) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Anticorps dirigés contre le récepteur de type ii d'une substance inhibitrice anti-mullérienne conçue de façon rationnelle
WO2018189379A1 (fr) * 2017-04-14 2018-10-18 Gamamabs Pharma Composés de liaison à l'amhrii pour la prévention ou le traitement de cancers
WO2018189381A1 (fr) * 2017-04-14 2018-10-18 Gamamabs Pharma Composés de liaison à l'amhrii pour la prévention ou le traitement de cancers du poumon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968470B1 (fr) * 2013-03-12 2020-10-28 The General Hospital Corporation Protéines de substance d'inhibition mullerienne (mis) modifiées et leurs utilisations pour le traitement de maladies
US20170218091A1 (en) * 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
WO2016030901A1 (fr) * 2014-08-31 2016-03-03 Tel Hashomer Medical Research Infrastructure And Services Ltd. Procédés pour empêcher l'activation des follicules prématurée
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US20170258842A1 (en) * 2016-03-09 2017-09-14 Augusta University Research Institute, Inc. Methods and Compositions for Treating Ovarian Failure
US11518793B2 (en) * 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012166712A1 (fr) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Anticorps dirigés contre le récepteur de type ii d'une substance inhibitrice anti-mullérienne conçue de façon rationnelle
WO2018189379A1 (fr) * 2017-04-14 2018-10-18 Gamamabs Pharma Composés de liaison à l'amhrii pour la prévention ou le traitement de cancers
WO2018189381A1 (fr) * 2017-04-14 2018-10-18 Gamamabs Pharma Composés de liaison à l'amhrii pour la prévention ou le traitement de cancers du poumon

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IMBEAUD SANDRINE ET AL: "Insensitivity to anti-Müllerian hormone due to a mutation in the human anti-Müllerian hormone receptor", NATURE GENETICS, vol. 11, no. 4, 1 December 1995 (1995-12-01), New York, pages 382 - 388, XP093090133, ISSN: 1061-4036, DOI: 10.1038/ng1295-382 *
SALHI I ET AL: "The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY, GB, vol. 379, no. 3, 1 May 2004 (2004-05-01), pages 785 - 793, XP002423288, ISSN: 0264-6021, DOI: 10.1042/BJ20031961 *
See also references of WO2020243679A1 *

Also Published As

Publication number Publication date
EP3976629A1 (fr) 2022-04-06
US20220073633A1 (en) 2022-03-10
US20230295318A1 (en) 2023-09-21
US11535676B2 (en) 2022-12-27
CA3139956A1 (fr) 2020-12-03
WO2020243679A1 (fr) 2020-12-03
AU2020282359A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
EP3864013A4 (fr) Agonistes du récepteur des hormones thyroïdiennes
EP3807267A4 (fr) Agonistes du récepteur de l'hormone thyroïdienne et utilisations associées
IL276730A (en) GAN-CNN for MHC peptide binding prediction
EP4069686A4 (fr) Agoniste du récepteur glp-1
EP3927693A4 (fr) Nouveaux composés et leurs utilisations en tant qu'agonistes du récepteur de l'hormone thyroïdienne
EP3893913A4 (fr) Peptides ciblant un récepteur de la transferrine
IL277044A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
IL290268A (en) Antigen binding proteins that specifically bind mage-a
EP3840755A4 (fr) Composés agonistes des récepteurs bêta des hormones thyroïdiennes
EP3863635A4 (fr) Composés agonistes du récepteur bêta des hormones thyroïdiennes
EP4017875A4 (fr) Composés agonistes du récepteur bêta de l'hormone thyroïdienne
IL283800A (en) Insulin analogs with reduced affinity for the insulin receptor
AU2020243430A1 (en) Antigen binding proteins
EP3647321A4 (fr) Peptide pour l'inhibition du récepteur de type toll (tlr) et composition pharmaceutique le comprenant
EP4028008A4 (fr) Composés agonistes du récepteur bêta de l'hormone thyroïdienne
EP4028409A4 (fr) Nouveaux peptides
EP3858868A4 (fr) Composition de polypeptide
IL289209A (en) A method for peptide characterization: mhc that binds polypeptides
EP3768722A4 (fr) Nouveau polypeptide d'anticorps anti-egfr
EP3976629A4 (fr) Peptides se liant au récepteur de l'hormone anti-müllérienne
EP3755327A4 (fr) Anticorps antagonistes du peptide lié au gène de la calcitonine (cgrp)
AU2019350356A1 (en) Arginase1 polypeptides
EP3936860A4 (fr) Système de chromatographe de distribution
GB201900443D0 (en) Cell-penetrating peptides
IL291364A (en) Antigen binding proteins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231024

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/72 20060101ALI20231018BHEP

Ipc: C07K 7/08 20060101AFI20231018BHEP